Korsana Biosciences to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Management will participate in four investor conferences from November 9-17, 2026
- ➤KRSA-028 is Korsana’s lead next-generation shuttled antibody targeting amyloid beta
- ➤KRSA-028 is being developed for Alzheimer’s disease treatment
- ➤THETA™ technology aims to enable higher brain drug concentrations
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences. * Guggenheim 3rd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 9, 2026, at 10:00 a.m. ET in Boston, MA. * Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026, at 1:20 p.m. ET in New York, NY. * UBS Global Biopharma Conference 2026: Fireside chat on Monday, November 16, 2026, at 3:20 p.m. GMT in London, UK. * Jefferies London Healthcare Conference: Presentation on Tuesday, November 17, 2026, at 3:00 p.m. GMT in London, UK. Live webcasts of the presentations will be available in the Investors section of the Company’s website at https://investors.korsana.com/news-events/events-presentations. Replays of the webcasts will be archived on the Company’s website for 90 days following the events.
Get started
Create a free account to read the full story.